180 related articles for article (PubMed ID: 24146762)
41. Calcineurin inhibitor conversion to rapamycin can improve graft function in living donor kidney transplantation with older donors.
Chen GD; Liu XC; Shi L; Qiu J; Wang CX; Fei JG; Li J; Huang G; Chen LZ
Transplant Proc; 2013 May; 45(4):1648-50. PubMed ID: 23726640
[TBL] [Abstract][Full Text] [Related]
42. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
[TBL] [Abstract][Full Text] [Related]
43. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
Karie-Guigues S; Janus N; Saliba F; Dumortier J; Duvoux C; Calmus Y; Lorho R; Deray G; Launay-Vacher V; Pageaux GP
Liver Transpl; 2009 Sep; 15(9):1083-91. PubMed ID: 19718632
[TBL] [Abstract][Full Text] [Related]
44. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
[TBL] [Abstract][Full Text] [Related]
45. Renal impairment after liver transplantation - a pilot trial of calcineurin inhibitor-free vs. calcineurin inhibitor sparing immunosuppression in patients with mildly impaired renal function after liver transplantation.
Gerhardt T; Terjung B; Knipper P; Palmedo H; Woitas RP; Kalff J; Sauerbruch T; Spengler U
Eur J Med Res; 2009 May; 14(5):210-5. PubMed ID: 19541578
[TBL] [Abstract][Full Text] [Related]
46. Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal.
Heilman RL; Younan K; Wadei HM; Mai ML; Reddy KS; Chakkera HA; Gonwa TA
Transplantation; 2011 Oct; 92(7):767-73. PubMed ID: 21775930
[TBL] [Abstract][Full Text] [Related]
47. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
[TBL] [Abstract][Full Text] [Related]
48. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
[TBL] [Abstract][Full Text] [Related]
49. A randomized, prospective comparison of transition to sirolimus-based CNI-minimization or withdrawal in African American kidney transplant recipients.
Fleming JN; Taber DJ; Pilch NA; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD; Bratton CF
Clin Transplant; 2016 May; 30(5):528-33. PubMed ID: 26914542
[TBL] [Abstract][Full Text] [Related]
50. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
51. The safety and efficacy of early withdrawal of calcineurin inhibitors in kidney transplant recipients 6 months' posttransplant.
Boswell A; Evans L; Rigg K; Shehata M
Transplant Proc; 2005 Mar; 37(2):884-5. PubMed ID: 15848564
[TBL] [Abstract][Full Text] [Related]
52. Proteinuria following a switch from calcineurin inhibitors to sirolimus.
Letavernier E; Pe'raldi MN; Pariente A; Morelon E; Legendre C
Transplantation; 2005 Nov; 80(9):1198-203. PubMed ID: 16314786
[TBL] [Abstract][Full Text] [Related]
53. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
[TBL] [Abstract][Full Text] [Related]
54. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
[TBL] [Abstract][Full Text] [Related]
55. Calcineurin inhibitor-free monotherapy in human leukocyte antigen–identical live donor renal transplantation.
Venot M; Abboud I; Duboust A; Michel C; Suberbielle C; Vérine J; Flamant M; Morelon E; Glotz D; Peraldi MN
Transplantation; 2011 Feb; 91(3):330-3. PubMed ID: 21344733
[TBL] [Abstract][Full Text] [Related]
56. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
[TBL] [Abstract][Full Text] [Related]
57. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience.
Lobach NE; Pollock-Barziv SM; West LJ; Dipchand AI
J Heart Lung Transplant; 2005 Feb; 24(2):184-9. PubMed ID: 15701435
[TBL] [Abstract][Full Text] [Related]
58. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
[TBL] [Abstract][Full Text] [Related]
59. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
Holdaas H; Rostaing L; Serón D; Cole E; Chapman J; Fellstrøm B; Strom EH; Jardine A; Midtvedt K; Machein U; Ulbricht B; Karpov A; O'Connell PJ;
Transplantation; 2011 Aug; 92(4):410-8. PubMed ID: 21697773
[TBL] [Abstract][Full Text] [Related]
60. Calcineurin-inhibitor free immunosuppression with mycophenolate mofetil and corticosteroids in paediatric renal transplantation improves renal allograft function without increasing acute rejection.
Krischock L; Gullett A; Bockenhauer D; Rees L; Trompeter RS; Marks SD
Pediatr Transplant; 2009 Jun; 13(4):475-81. PubMed ID: 18992054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
